Use of drug reduces likelihood of progression to multiple sclerosis

April 19, 2012 in Inflammatory disorders

People who received injections of the multiple sclerosis (MS) drug interferon beta-1a soon after their first signs of possible MS were less likely to progress to clinically definite MS than people who switched to interferon beta-1a from placebo, according to new phase three results of the three-year REFLEXION clinical trial that will be presented as part of the Emerging Science program (formerly known as Late-Breaking Science) at the American Academy of Neurology's 64th Annual Meeting in New Orleans, April 21 to April 28, 2012.

The trial was conducted with the human serum albumin-free formulation of interferon beta-1a, which is now available in all European Union countries, Australia, Canada and Switzerland, as well as a number of countries in Asia, Latin America, Africa and the Middle East. It is not available in the United States.

"While we've known it's beneficial to start MS drugs as soon as possible, this is the first trial to show a benefit of early injections of interferon beta-1a treatment at three years," said Mark Freedman, MD, with the University of Ottawa in Ontario, Canada, and a Fellow of the American Academy of Neurology.

The three-year clinical trial involved 517 people who had experienced a first clinical episode suggestive of a demyelinating event, such as tingling, numbness, muscle weakness or problems with balance, along with having at least two clinically silent detected by a brain .

For two years, one-third of the participants received 44 mcg of interferon beta-1a subcutaneously three times a week; one-third received 44 mcg of the drug once a week, which is an unapproved dosage; and another one-third received placebo for two years or until experiencing a second clinical episode, at which point they were switched to three-times-weekly dosing. After the two years were over, the 133 people who were still receiving the placebo were switched to the three-times-weekly dose and the others continued their originally allocated dosages. The participants started their treatment an average of 58 days after their first symptoms.

After the third year of the study, the researchers found that those who had been receiving the drug three times a week or once a week for the duration of the trial were less likely to be diagnosed with clinically definite MS (defined as having a second clinical attack or a sustained increase in the Expanded Disability Status Scale disability score of greater than 1.5) than those who had initially received the placebo. The cumulative probability of being diagnosed with clinically definite MS by the end of the third year was 41 percent for the delayed treatment group (people who had switched from placebo to three-times-weekly treatment), 28 percent for those who had received once-a-week treatment all three years, and 27 percent for those who had three-times-weekly treatment for three years.

The study also found that those who had received the treatment for the full three years were less likely to meet the McDonald criteria for a MS diagnosis, a different measure than the one for clinically definite MS that includes an evaluation of MRI. A total of 87 percent of people who had switched from placebo to the treatment after two years met the McDonald criteria for MS after three years, compared with 79 percent of those who had received the weekly treatment and 67 percent of those who had treatments three times a week.

"While doses three times a week and once a week equally delayed a clinically definite MS diagnosis without MRI measures, there were significantly more benefits in taking the drug three times a week compared with once a week when it came to brain lesion changes and other McDonald criteria for diagnosing MS," said Freedman.

The REFLEXION trial is ongoing and will provide long-term data out to five years.

The most common adverse events in the trial were flu-like symptoms, injection site reactions and headache.

Provided by American Academy of Neurology search and more info website

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Researchers find common childhood asthma unconnected to allergens or inflammation

Little is known about why asthma develops, how it constricts the airway or why response to treatments varies between patients. Now, a team of researchers at Weill Cornell Medical College, Columbia University Medical Center ...

Inflammatory disorders created May 23, 2013 | popularity not rated yet | comments 0 | with audio podcast

Asthma symptoms impair sleep quality and school performance in children

The negative effects of poorly controlled asthma symptoms on sleep quality and academic performance in urban schoolchildren has been confirmed in a new study.

Inflammatory disorders created May 21, 2013 | popularity not rated yet | comments 0

Inflammatory bowel disease raises risk of melanoma

Patients with inflammatory bowel disease (IBD) are at higher risk of melanoma, a form of skin cancer, report researchers at Mayo Clinic. Researchers found that IBD is associated with a 37 percent greater risk for the disease. ...

Inflammatory disorders created May 20, 2013 | popularity 4.5 / 5 (2) | comments 0

A new 'on' signal for inflammation

(Medical Xpress)—Inflammation is an important response in the body - it helps you to kill off invaders such bacteria that could cause a harmful infection. But if it's chronic or uncontrolled, inflammation can also cause ...

Inflammatory disorders created May 14, 2013 | popularity 5 / 5 (1) | comments 0 | with audio podcast

New research reveals swimming beneficial for young people with asthma

New research by medical students working in the Breathe Well Centre of Research Excellence at the UTAS School of Medicine has revealed swimming has health benefits for young people with asthma, with no adverse effects on ...

Inflammatory disorders created May 10, 2013 | popularity 5 / 5 (1) | comments 0


Researchers identify first drug targets in childhood genetic tumor disorder

Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...

Engineered cytomegalovirus protects monkeys from HIV equivalent

(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...

Hormone levels may provide key to understanding psychological disorders in women

Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.

Going live: Immune cell activation in multiple sclerosis

Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...

Driving and hands-free talking lead to spike in errors, study shows

Talking on a hands-free device while behind the wheel can lead to a sharp increase in errors that could imperil other drivers on the road, according to new research from the University of Alberta.

Pollen count apps for smartphones are nothing to sneeze at

Kate O'Reilly's spring allergy survival kit includes the usual stuff - nasal sprays, allergy pills and a box of tissues. This season, she's added a new weapon to her line of defense: an app on her smartphone.